Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Finans |
| Industri | Investeringar |
Katalysen's portfolio company Venture Targeter AB ("Venture Targeter") recently announced its inaugural investment into biotech company QuTEM (formerly Vironova BioAnalytics). Readers will find a more detailed presentation (PDF) attached with this press release.
Venture Targeter, established by Katalysen Ventures AB (publ) ("Katalysen"), is dedicated to identifying, structuring, and executing special situation investments in collaboration with co-investors and industry experts.
Specializing in distressed assets and the turnaround of companies to maximize value extraction, Venture Targeter is particularly drawn to opportunities with a 2-3X potential on day 1 and a minimum 10X potential over a 3-year horizon.
Peter Almberg, CEO at Katalysen Ventures, comments: "Numerous opportunities similar to our initial QuTEM transaction are present, as many capable businesses currently struggle in the present market conditions. Successfully turning around such ventures requires engaging the right team, partners, experience, expertise, and local presence. We are proactively exploring such potential opportunities."
As a 33% stakeholder in Venture Targeter, Katalysen contributes crucial experience, network and expertise, essential for the identification, structuring, turnaround and exiting of such investments.
As announced on 22/11/2023, Venture Targeter successfully completed its inaugural special situation investment in the biotech firm QuTEM (formerly Vironova BioAnalytics), once valued at SEK 2+ BN. Venture Targeter invested into QuTEM as a part of a consortium with a winning offer for the bancrupty estate.
Less than two months post-transaction, a valuation report assessed QuTEM at a SEK 230 M, more than 15X above the valuation at Venture Targeter's point of entry. The resulting value of Katalysen Ventures' share was communicated on 06/12/2023.
An exit strategy for QuTEM is anticipated within the next 3 years, whether through a trade sale or IPO.
In line with Katalysen's strategic goals, Venture Targeter is focused on executing 2-3 comparable transactions annually, thereby potentially generating substantial value for Katalysen's shareholders.
Readers will find a more detailed presentation (PDF) attached with this press release, and at www.katalysen.com. If you want to request access to the full valuation report please contact Peter Almberg at pa@katalysen.com.